Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 30, 2025HaematologicaOpen Access

Hematopoietic cell transplantation after CD19-directed CAR T-cell therapy for remission consolidation or relapse treatment in pediatric acute lymphoblastic leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

RMRegina M. MyersYLYimei LiHLHongyan Liu

Discussion

Loading...

Member takes

Overview

Retrospective review shows hematopoietic cell transplantation improves disease-free survival in pediatric B-ALL, indicating effective relapse management.

Key Points

  • Overall survival after hematopoietic cell transplantation was 95% in the preemptive cohort of children with B-ALL, illustrating its effectiveness.
  • The study involved a cohort of 47 children and young adults undergoing first hematopoietic cell transplantation after CAR T-cell therapy.
  • A median follow-up of 4.1 years revealed a 64% disease-free survival rate for those receiving treatment after relapse.
  • Hematopoietic cell transplantation may enable durable remission in B-ALL cases following CD19-directed CAR T-cell therapy.

Cite This Study

Myers et al. (2025) studied this question.

synapsesocial.com/papers/692b9d9a1d383f2b2a37a12bhttps://doi.org/10.3324/haematol.2025.288303
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Allogeneic hematopoietic cell transplantation following chimeric antigen receptor T-cell (CAR-T) therapy in B-cell acute lymphoblastic leukemia (B-ALL): A systematic review and meta-analysis.2026
  2. 2Pre-transplant CAR T-cell therapy is associated with inferior survival and increased non-relapse mortality in pediatric B-ALL: A single-center retrospective analysis2025
  3. 3Maintenance after CAR T? Are we there yet? Reducing the risk of relapse after loss of anti-CD19 CAR T <i>-</i> cell persistence in ALL2025
  4. 4Comparison of Allo-HSCT outcomes after CAR-T therapy versus chemotherapy in pediatric patients with relapsed/refractory B-ALL: a retrospective study2026
  5. 5Optimizing Allogeneic Stem Cell Transplantation Following CAR-T Therapy in Acute Lymphoblastic Leukemia2024